Bortezomib (Velcade) in Patients With Untreated Multiple Myeloma
Status:
Completed
Trial end date:
2008-09-01
Target enrollment:
Participant gender:
Summary
Bortezomib (Velcade) has just recently been approved by the FDA for the treatment of multiple
myeloma in patients who have received at least two prior therapies and have demonstrated
disease progression on the last therapy. This study will determine if Velcade is effective in
treating patients with multiple myeloma that have had no prior treatment for the disease. We
will also use whole-genome scanning to identify drug response biomarkers in bone marrow
samples as well as nerve fiber studies to compare nerves prior to the use of Velcade and
after treatment with Velcade.
Phase:
Phase 2
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborators:
Beth Israel Deaconess Medical Center Brigham and Women's Hospital Emory University Massachusetts General Hospital Memorial Sloan Kettering Cancer Center Millennium Pharmaceuticals, Inc. Roswell Park Cancer Institute